PRESS RELEASE
PrecisionLife and Metrodora Institute share first insights with ME/CFS, Long COVID participants in MetX research study
MetX funded by $1M grant from Metrodora Foundation to accelerate research for complex multisystem disorders
SALT LAKE CITY, UT and OXFORD, UK – 18 September 2024 – PrecisionLife, a leading clinical-stage precision medicine company focused on chronic diseases, and Metrodora Institute, an advanced US research and healthcare center, have begun sharing the first research results with participants from Metrodora’s MetX study. The Metrodora Foundation, a leading 501(c)(3) nonprofit, provided critical funding to launch MetX with a generous $1M grant.
This marks a significant breakthrough in precision medicine approaches for complex, chronic conditions including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID, as it is the first time PrecisionLife’s groundbreaking disease models have been applied to explore new diagnostic tools and treatment options.
ME/CFS and Long COVID are complex, debilitating conditions affecting millions of people worldwide and costing billions of dollars in healthcare. Despite extensive research over the years, effective diagnostic tests and treatments remain elusive. These diseases are poorly understood, leaving patients without clear answers or effective therapies.
“The speed and precision of our progress in these trials is remarkable,” said Steve Gardner, CEO of PrecisionLife. “We identified and published the first-ever replicated genetic associations in both ME/CFS and Long COVID. Within six months, our partners at Metrodora Institute have designed, recruited, and returned the first research results for groundbreaking diagnostic tests incorporating our unique disease insights. We’re confident that the supporting systems and workflows are in place to support further trials and tests. Our partnership with Metrodora has the potential to transform the lives of tens of millions of patients affected by these and many other debilitating diseases.”
Participants receive a detailed research report that identifies the underlying mechanisms of their disease, leading to more accurate diagnoses and the possibility of tailored therapies. Recruitment will be expanded to 1,000 participants and aims to validate these new genotypic tests thanks to support from the Metrodora Foundation.
“To drive real progress for our patients, we have created a comprehensive landmark dataset that can be analyzed using cutting-edge technologies,” said Amy Rochlin, Metrodora Foundation’s Executive Director. “MetX transforms patient engagement by involving them as active partners in critical research and delivering essential data back to them. This study has the massive potential to unlock significant breakthroughs and deliver much-needed clarity in diagnosing and treating these complex diseases and revolutionizing care for countless individuals who currently have few effective options.”
Participants in the MetX study may also be invited to join focused trials in the near future that evaluate the effectiveness of repurposed drug candidates targeting their specific disease mechanisms. If these drugs prove effective, they could demonstrate the potential of precision medicine to modify diseases and accelerate the development of new, targeted treatments that improve patient outcomes.
Recruitment for the MetX study is ongoing in the US. For more information and to join the study, please visit the MetX study website at research.Metrodora.co.
ENDS
About PrecisionLife®
PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs.
Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them.
With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines.
To learn more about PrecisionLife, visit precisionlife.com.
PrecisionLife media requests:
Noah Konig
Marketing Director
press@precisionlife.com
About Metrodora Institute
Located in Salt Lake City, Utah, the Metrodora Institute was founded in 2021 with the vision of reimagining care and accelerating research to improve the treatment of complex multisystem disorders. Through physician and patient partnerships, Metrodora is uniquely positioned to develop and commercialize new diagnostic tests and therapeutics for those living with these debilitating conditions. Metrodora Institute has created an innovative offering with access to advanced tools and world-class expertise in neurology, gastroenterology, immunology, autoimmunity, pain and metabolic disorders.
About Metrodora Foundation
The Metrodora Foundation is an innovative, patient-founded, patient-focused 501(c)(3) nonprofit organization with a mission to accelerate data-driven research for complex multisystem disorders such as Long COVID, POTS, ME/CFS, EDS/HSD and other conditions that impact multiple body systems. The Metrodora Foundation is catalyzing an entire research ecosystem by funding and uniting a premier coalition of top scientists, clinicians, foundations, academic institutions and cutting-edge technology companies to drive groundbreaking advancements in this critical, underserved medical field. To learn more about the work of the Metrodora Foundation, please visit www.metrodora.org.
Metrodora media requests:
Summer Dashe
VP of Marketing and Communications
media@metrodora.co
World leading ME/CFS research
For further information about our groundbreaking research in ME/CFS, click on the link below.
